Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for determining that an action is to be performed, and in response, selecting a telemedicine session action to be performed, the telemedicine session action associated with a user; based on selecting the telemedicine session action, identifying a complexity level associated with a medical condition of the user, the medical condition associated with the telemedicine session action; determining that the complexity level includes a first complexity level, and in response, identifying i) a first communication event and ii) a first time threshold associated with the first communication event; and determining that the first time threshold is satisfied, and in response, satisfying the first communication event.

Abstract: A lens refinishing process includes preparing the surface of the lens, determining whether to coat the lens with a polymer coating or polish the lens, either applying a polymer coating to the lens or polishing the lens, and then applying a protective coating. The preparation step includes applying a removal compound to the lens to remove an anti-reflective coating and to create nano-scratches, applying a coupling agent to the exposed substrate, and heating the coupling agent. The polishing step includes iteratively polishing the substrate using different combinations of polishing compound with different grit values together with different types of polishing pads.

Abstract: Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.

Abstract: Disclosed are immediate release oral tranexamic acid formulations and methods of treatment therewith.

Abstract: Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.

Abstract: An input image (7) having a first pixel resolution is acquired from an image capture system (2). A respective characterization of each of at least one visual quality feature of the input image (7) is determined. An output thumbnail image (9) is produced from the input image (7). The output thumbnail image (9) reflects the respective characterization of each visual quality feature. The output thumbnail image (9) has a second pixel resolution lower than the first pixel resolution. The output thumbnail image (9) is output in association with operation of the image capture system (2).

Abstract: Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.

Abstract: The presently disclosed subject matter is directed to a package that allows substantially the entire surface of a product (such as fresh red meat) to be in contact with a desired internal gas concentration. In addition, the disclosed package ensures that large amounts of the product surface are not in contact with the packaging materials to prevent discolored product areas. Particularly, the disclosed package comprises a support member, a thermoformed lidding film, and an oxygen-sensitive product. The lidding film includes one or more ridges that prevent direct contact with the product. As a result, uniform product color is maintained and the product appearance is preserved.

Abstract: Disclosed are immediate release oral tranexamic acid formulations and methods of treatment therewith.

Abstract: Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.

Abstract: The invention is directed to a method of administering hydrogen sulfide (H2S) slowly and sustainably to an individual in need thereof comprising administering an effective amount of a compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.

Abstract: Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.

Abstract: Systems and methods for securing a document for transmission are discussed. In one embodiment, a document is checked for an indication of confidentiality. The document is then passed to a secure driver, in response to a finding of the indication of confidentiality. The document is passed to a non-secure driver, in response to a failure to find the indication of confidentiality. The document is then transmitted after processing by the secure driver or the non-secure driver.

Abstract: A computer-implemented method according to an embodiment of the present disclosure comprises: providing one or more questions to a lead; receiving a respective one or more answers to the one or more questions from the lead; identifying, by the computer system based on the one or more answers, one or more client organizations for matching with the lead; confirming interest by the lead in a client organization of the one or more client organizations; and transferring the lead to the confirmed client organization.

Abstract: A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.

Abstract: The presently disclosed subject matter is directed to an article that enables on-demand blooming of an oxygen-sensitive product packaged within the interior of the article. Specifically, the product can be packaged between two films, wherein at least one of the films is oxygen-permeable. The edges of the films can be attached to one or more suspension frames, such that the product is suspended between the two frames. The oxygen-impermeable film is covered in with an oxygen-impermeable material that can be removed on demand to promote blooming.

Abstract: A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.

Abstract: The invention is directed to a method of administering hydrogen sulfide (H2S) slowly and sustainably to an individual in need thereof comprising administering an effective amount of a compound represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

Abstract: A scent control system for use in a hunting blind enclosure includes an exhaust conduit adapted to exhaust air from the hunting blind enclosure and an air driver in fluid communication with the exhaust conduit. The air driver is operable to intake air from within the enclosure and exhaust air through the exhaust conduit and is further adapted to provide a negative air pressure within the enclosure relative to an air pressure outside of the enclosure. A filter disposed between an outlet of the air driver and the exhaust conduit filters human scent from air being exhausted from the enclosure.